<DOC>
	<DOCNO>NCT01682616</DOCNO>
	<brief_summary>This Phase 1b , open-label , multicenter study evaluate safety tolerability ABT-199 combination rituximab 50 subject Relapsed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma . The primary objective study assess safety profile , determine maximum tolerate dose establish Recommended Phase Two Dose ABT-199 administer combination rituximab . The dose escalation portion study include approximately 30 subject . Once recommended phase two dose schedule determine , 20 additional subject enrol expanded safety portion study . Subjects meet criterion CR , CRi , MRD-negative PR study may discontinue ABT 199 . If disease progression occur , define iwCLL NCI/WG criterion tumor response , subject may re-initiate ABT-199 .</brief_summary>
	<brief_title>A Phase 1b Study Evaluating Safety Tolerability ABT-199 Combination With Rituximab Subjects With Relapsed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Subject must great equal 18 year age . Subject must relapse Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma . Subject Eastern Cooperative Oncology Group performance score less equal 1 . Subject must adequate bone marrow independent growth factor support per local laboratory reference range Screening . Subject must adequate coagulation , renal , hepatic function , per laboratory reference range Screening . Chronic lymphocytic leukemia Small Lymphocytic Lymphoma subject undergone allogeneic autologous stem cell transplant . Subject uncontrolled autoimmune hemolytic anemia thrombocytopenia . Subject test positive human immunodeficiency virus . Seropositivity hepatitis B surface antigen hepatitis C virus antibody ribonucleic acid . History severe allergic anaphylactic reaction rituximab . Subject receive live viral vaccine within 6 month prior first dose study drug . Subject receive monoclonal antibody antineoplastic intent within 8 week prior first dose study drug . Subject receive follow within 14 day prior first dose study drug , recover less grade 2 clinically significant adverse effect ( ) /toxicity ( ) previous therapy : Any anticancer therapy include chemotherapy , immunotherapy , radiotherapy ; Investigational therapy , include target small molecule agent . Subject cardiovascular disability status New York Heart Association Class great equal 2 . Class 2 define cardiac disease subject comfortable rest ordinary physical activity result fatigue , palpitation , dyspnea anginal pain . Subject significant history renal , neurologic , psychiatric , pulmonary , endocrinologic , metabolic , immunologic , cardiovascular , hepatic disease opinion investigator would adversely affect his/her participate study . Subject history active malignancy CLL/SLL within past 2 year prior study entry , exception : Adequately treat situ carcinoma cervix uterus ; Basal cell carcinoma skin localize squamous cell carcinoma skin ; Previous malignancy confine surgically resect ( treated modality ) curative intent . Subject malabsorption syndrome condition preclude enteral route administration . Subject exhibit evidence clinically significant ongoing recent condition ( ) include , limited : Ongoing systemic infection ( viral , bacterial , fungal ) ; Diagnosis fever neutropenia within 1 week prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Venetoclax</keyword>
	<keyword>ABT-199</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Preliminary</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Safety</keyword>
	<keyword>Cancer</keyword>
</DOC>